
    
      The total study duration for one patient is up to 11 weeks, including a screening period of
      up to 6 weeks run-in (depending on washout requirements), a 4-week treatment period, and a
      1-week follow-up period.

      The study design is also a parallel cohort study to assess the safety, tolerability, and
      pharmacodynamic activity of SAR366234.
    
  